AKT3 and myeloproliferative neoplasm: The data obtained reveal that among the 445 samples collected at diagnosis, those from patients who developed a prior MDS or a prior MPN exhibit a higher level of AKT3 expression (although not significant for the “prior MPN” category likely due to an insufficient number of samples), but not of AKT1 or AKT2 (Fig. 6, right).